In that study, the authors evaluated TP53 mutation in NSCLC, namely, adenocarcinoma and squamous cell carcinoma, while in our study TP53 mutation and its correlation with ERs were evaluated exclusively in adenocarcinoma. This evidence concerns the gene TP53 and adenocarcinoma.